Views & Analysis Healthcare evidence development: guilty until proven innocen... Pharma must prepare its case meticulously to support its new drug applications.
Views & Analysis Behind the buzz of real-world data and real-world evidence Putting the who, where and why of real-world studies into context.
Views & Analysis Integrating patient insights and real-world data: the future... Drugs development in 2017 looks very different to how it did 10 years ago, and it’s still evolving.
Debates & Insight Sponsored Approval and access: overcoming the final hurdle of drug dev... 2017 is likely to be a year of significant change for pharma brands in Europe. With affordability on the agenda for almost every country in the region, a move toward greater col
Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Views & Analysis Rare diseases and orphan drugs need digital innovation mHealth tech can provide longer-term monitoring for clinical trials.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
